HR and breast cancer: In addition, PALOMA‐1, PALOMA‐2, MONARCH‐3, MONALEESA‐2, and MONALEESA‐7 have investigated the use of CDK4/6 inhibitors in combination with ET as first‐line treatment for HR+/HER2− BC, showing a notable improvement in PFS compared with ET alone [302].